HighVista Strategies’s Akero Therapeutics AKRO Stock Holding History

HighVista Strategies’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-110,079	Closed	-$5.23M	–	147
2025 Q3	$5.23M	Buy	110,079 +50,086	+83%	+$2.43M	1.28%	19
2025 Q2	$3.2M	Buy	59,993 +35,926	+149%	+$1.63M	1.18%	13
2025 Q1	$974K	Buy	24,067 +11,538	+92%	+$489K	0.38%	113
2024 Q4	$349K	Buy	+12,529	New	+$379K	0.13%	134
2023 Q4	–	Sell	-11,408	Closed	-$577K	–	128
2023 Q3	$577K	Buy	+11,408	New	+$531K	0.27%	90
2023 Q2	–	Sell	-18,629	Closed	-$713K	–	136
2023 Q1	$713K	Hold	18,629	–	–	0.58%	59
2022 Q4	$1.02M	Buy	+18,629	New	+$798K	0.61%	42
2021 Q1	–	Sell	-27,739	Closed	-$716K	–	127
2020 Q4	$716K	Buy	+27,739	New	+$772K	0.46%	53

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HighVista Strategies's AKRO Position: Q4 2025 in Review

HighVista Strategies sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 110,079 shares — an estimated $5.23M sold.

HighVista Strategies first reported a position in AKRO in Q4 2020 and held it in 8 quarters. The position peaked at $5.23M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

HighVista Strategies reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
HighVista Strategies sold 110,079 Akero Therapeutics shares in Q4 2025, an estimated $5.23M.
HighVista Strategies first reported a position in Akero Therapeutics in Q4 2020 and held it in 8 quarters.
HighVista Strategies's Akero Therapeutics position peaked at $5.23M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.